DelveInsight's latest pipeline report reveals over 10 companies actively developing treatments for pulmonary sarcoidosis. Key players including Novartis and aTyr Pharma are advancing innovative therapies, with CMK389 and ATYR1923 showing particular promise in clinical development.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.